ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Rating Upgraded by Wall Street Zen

ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other equities research analysts have also recently weighed in on the stock. Oppenheimer increased their price target on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the company a “market perform” rating in a research report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. BMO Capital Markets upped their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Finally, Bank of America reissued a “buy” rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.44.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $29.21 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $19.69 and a fifty-two week high of $29.48. The stock has a 50 day moving average price of $24.39 and a two-hundred day moving average price of $23.26. The company has a market capitalization of $5.03 billion, a P/E ratio of 13.16, a PEG ratio of 23.76 and a beta of 0.81.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. During the same quarter in the prior year, the firm posted $0.16 earnings per share. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. As a group, equities analysts predict that ACADIA Pharmaceuticals will post 0.57 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 14,292 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the completion of the sale, the executive vice president directly owned 67,828 shares of the company’s stock, valued at approximately $1,981,934.16. This trade represents a 17.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the sale, the insider directly owned 24,509 shares in the company, valued at $519,100.62. The trade was a 18.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 42,100 shares of company stock worth $1,134,287 over the last quarter. Corporate insiders own 26.20% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACAD. Farther Finance Advisors LLC boosted its position in ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $26,000. Transamerica Financial Advisors LLC raised its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 1,185 shares during the period. Finally, Leonteq Securities AG purchased a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $52,000. 96.71% of the stock is owned by institutional investors.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.